Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (253)	1/30/1998 11:20:00 AM
From: Don W Stone	Respond to of 507

Rick:Take it easy on me, will you, I am not that hard to get along with. Well anyway, here are three statements taken directly from the Reuters news release of Oct.8, 1997. <<<< The likelihood of the mutant strain of the disease spreading across the continent will depend on which type of vaccine a country uses. The whole cell vaccine used by the Dutch has been ineffective. But other vaccines in England and Finland which give immunity to pertectin and other proteins will help sufferers fight the disease. " In such cases the mutation may cause a smaller or later epidemic," said Schellekens. >>>>> Now I will make the "irrisponsible suggestion" again that Dr. Schelleken is saying that "other vaccines ...... which give immunity to pertectin and other proteins will help sufferers fight the disease" and "in such cases the mutation may cause a smaller or later epidemic". The mutation we are talking about here involves the pertectin. In the case of the whole cell vaccine which is a multicomponent vaccine and includes a pertectin component this mutation tricks the immune system into not responding. i.e. efficacy went to hell. Got it? What is to say it won't happen with the multicomponent DTaP vaccines that have the pertectin component? Now you are a smart guy. How does the multicomponent DTaP differ from the old whole cell DTP in this regard? Just why wouldn't this mutation trick the DTaP vaccine that has the pertactin component in it just like it does with the wholecell? What will the efficacy really be? The answer is , the jury is out, we don't know.( I am sure the Connaughts and SKB's, and AHP are working the problem, for now i can only go on what I have come across on this subject, maybe they have pulled the pertactin component, who knows?) Now my " irrisponsible suggestion" is that Dr. Schellekens is saying that the multicomponent vaccines will HELP and when he states that the mutation MAY cause a smaller or later epidemic he does most certainly imply that he doesn't expect efficacy to be very good.That this mutation will negatively impact efficacy. Can you tell me why it won't? I don't think so. This is why we do cultures, conduct clinical trials,etc.The flu vaccine business deals with this type of problem on an annual basis. Right? Now I will tell you that this particular mutation will have no effect on CERTIVA. If I have offended you I am sorry. You are a BEAR, and I am a BULL. And yes I have just added another very significant reason to be very bullish on NVX. :-}:-}, :-}, :-}, :-}, :-}.

To: Rick Strange who wrote (253)	1/30/1998 12:03:00 PM
From: Don W Stone	Read Replies (1) \| Respond to of 507

RS: You said: <<<<<to suggest that because a vaccine has components other than PT it will cause an epidemic, is untrue! It was never stated in the story, and is an irrisponsible suggestion.>>>>>> Now you do realize that what you are saying reflects how you chose to interrupt what I said, and nothing more. I am saying that any vaccine that has the pertectin component is likely to be effected by this mutation in a negative manner. .i.e possibly have a lower efficacy , may be little more effective than the whole cell. Who knows? As to an epidemic what evber Dr. Schellekens says is all I am repeating . Nothing more , nothing less. I do like difference of opinion, but that is not is what is coming from you right now.